| Perspective |  |
Open Access |
Other Countries Are Not Paying Their Fair Share of the Cost of Biopharmaceutical Innovation – What Can the United States Do to Change That?
|
|
|
||
Downloads |
Comments |
Views |
|
Introduction |
|
|
Understanding the Roots of the Problem |
|
|
What a Country Pays Should Reflect Its Ability to Pay, Not Its Willingness to Pay |
|
|
International Reference Pricing, including a “Most Favored Nation” Drug Pricing Model, would be disastrous for the U.S. |
|
|
Trade Negotiations Happening Now Present an Opportunity for the U.S. Government to Ensure Other Developed Countries Pay Their Fair Share for Biopharmaceutical Innovation |
|
|
A More Equitable System |
|
|
References |
Reader Comments
Comment
We welcome and encourage comments from both scientists and the general public. Comments are moderated solely for appropriateness and will be posted after review.
May 18, 2025 10:15 AM
James Drouin
Simple Problems Have Simple Solutions
It's not difficult ... since the pharmaceutical companies are the ones who engaged in an illegal activity - "price fixing" - President Trump's Administration simply needs to hold the position that pharmaceutical companies have "X" amount of time, let's say thirty days, to correct their criminal actions or there will be criminal prosecutions.